Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pancreatic cancer
Biotech
Immuneering sees 94% survival at 6 months in pancreatic cancer
The data emboldened the biotech to start planning a pivotal trial to support accelerated approval of its MEK inhibitor.
Nick Paul Taylor
Jun 17, 2025 10:55am
OSE shares 65% OS rate behind cancer vaccine's phase 2 win
Jun 3, 2025 7:05am
Actuate's pancreatic cancer drug boosts survival by 3 months
Jun 2, 2025 7:30am
Novocure's TTFields clear phase 3 pancreatic cancer trial
Dec 2, 2024 11:30am
Alligator lets loose 70% of staff, sinking stock 53%
Dec 2, 2024 10:40am
FibroGen lays off 75% of US staff as asset flunks 2 more trials
Jul 31, 2024 7:22am
